{
    "clinical_study": {
        "@rank": "126145", 
        "arm_group": [
            {
                "arm_group_label": "Pimasertib Capsule/Pimasertib Tablet", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Pimasertib Tablet/Pimasertib Capsule", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase 1, multi-center, open-label, single-dose, 2 period, 2 sequence cross-over\n      trial to investigate the relative bioavailability of 2 solid oral pimasertib formulations in\n      cancer subjects (Part A), followed by open-label pimasertib administration (Part B and trial\n      extension phase)."
        }, 
        "brief_title": "Relative Bioavailability of Pimasertib in Cancer Patients", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically confirmed solid tumors, either refractory to standard therapy or for\n             which no effective standard therapy is available, with a measurable disease  as\n             defined by RECIST v1.1\n\n          -  An Eastern Cooperative Oncology Group Performance Status (ECOG PS) of less than or\n             equal to 1\n\n          -  Other protocol defined inclusion criteria could apply\n\n        Exclusion Criteria:\n\n          -  Disease conditions or concomitant medication that may significantly influence the\n             conduct of the trial or an abnormal electrocardiogram (ECG) or blood pressure at\n             Screening as defined in the protocol\n\n          -  Treatment with strong inhibitors or inducers of cytochrome P450 2C19 (CYP2C19) and\n             CYP3A4 including fruit juices or beverages containing these substances\n\n          -  History of prior mitogen-activated protein kinase/extracellular signal-regulated\n             kinase (MAPK/ERK) kinase (MEK) inhibitor exposure (including, pimasertib) or\n             progression of disease on MEK inhibitors\n\n          -  Evidence of a retinal vein occlusion (RVO) on fluorescein angiogram or a history of\n             RVO\n\n          -  Life expectancy of less than 12 weeks\n\n          -  Other protocol defined exclusion criteria could apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992874", 
            "org_study_id": "200066-013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pimasertib Capsule/Pimasertib Tablet", 
                "description": "Pimasertib capsule will be administered at a single dose of 60 milligram (mg) orally on Day 1 in Part A.", 
                "intervention_name": "Pimasertib Capsule (Part A)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "AS703026", 
                    "MSC1936369B"
                ]
            }, 
            {
                "arm_group_label": "Pimasertib Capsule/Pimasertib Tablet", 
                "description": "Pimasertib tablet will be administered at a single dose of 60 mg orally on Day 3 in Part A.", 
                "intervention_name": "Pimasertib Tablet (Part A)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "AS703026", 
                    "MSC1936369B"
                ]
            }, 
            {
                "arm_group_label": "Pimasertib Tablet/Pimasertib Capsule", 
                "description": "Pimasertib tablet will be administered at a single dose of 60 mg orally on Day 1 in Part A.", 
                "intervention_name": "Pimasertib Tablet (Part A)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "AS703026", 
                    "MSC1936369B"
                ]
            }, 
            {
                "arm_group_label": "Pimasertib Tablet/Pimasertib Capsule", 
                "description": "Pimasertib capsule will be administered at a single dose of 60 mg orally on Day 3 in Part A.", 
                "intervention_name": "Pimasertib Capsule (Part A)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "AS703026", 
                    "MSC1936369B"
                ]
            }, 
            {
                "arm_group_label": [
                    "Pimasertib Capsule/Pimasertib Tablet", 
                    "Pimasertib Tablet/Pimasertib Capsule"
                ], 
                "description": "Subjects who complete Part A will receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.", 
                "intervention_name": "Pimasertib Capsule (Part B and trial extension phase)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "AS703026", 
                    "MSC1936369B"
                ]
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Neoplasms", 
            "Pimasertib", 
            "Cancer"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rockland", 
                    "country": "United States", 
                    "state": "Massachusetts"
                }, 
                "name": "Please Contact U.S. Medical Information Located in"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-Center, Open-Label, Single 60 mg Dose, Two Period, Two Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Two Solid Oral Pimasertib Formulations in Cancer Patients", 
        "overall_official": {
            "affiliation": "EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Pharmacokinetics parameters: Cmax and AUC (0-t)", 
            "safety_issue": "No", 
            "time_frame": "Days 1 and 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992874"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics parameters: AUC (0-infinity), tmax, lambda_z, t1/2, CL/f, and Vz/f", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 3"
            }, 
            {
                "measure": "Number of Subjects With Treatment-Emergent Adverse Events (TEAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline up to 30 days after the last dose of study treatment"
            }, 
            {
                "measure": "Number of Subjects With Complete Response (CR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 3, Cycle 5 and thereafter Day 1 of every fourth cycle until disease progression, intolerable toxicity, withdrawal of consent or before start of a new anti-cancer therapy, assessed up to 200 days"
            }, 
            {
                "measure": "Number of Subjects With Partial Response (PR) according to RECIST v1.1", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 3, Cycle 5 and thereafter Day 1 of every fourth cycle until disease progression, intolerable toxicity, withdrawal of consent or before start of a new anti-cancer therapy, assessed up to 200 days"
            }, 
            {
                "measure": "Number of Subjects With Stable Disease (SD) according to RECIST v1.1", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 3, Cycle 5 and thereafter Day 1 of every fourth cycle until disease progression, intolerable toxicity, withdrawal of consent or before start of a new anti-cancer therapy, assessed up to 200 days"
            }, 
            {
                "measure": "Number of Subjects With Progressive Disease (PD) according to RECIST v1.1", 
                "safety_issue": "No", 
                "time_frame": "Day 1 of Cycle 3, Cycle 5 and thereafter Day 1 of every fourth cycle until disease progression, intolerable toxicity, withdrawal of consent or before start of a new anti-cancer therapy, assessed up to 200 days"
            }
        ], 
        "source": "EMD Serono", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EMD Serono", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}